1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood conditions

Crizanlizumab for preventing sickle cell crises in sickle cell disease

Technology appraisal guidance [TA743] Published: 03 November 2021

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 162 KB 03 November 2021  

Final draft guidance

  • Final draft guidance  
  • Final appraisal document PDF 257 KB 05 October 2021  
  • Committee papers PDF 1.91 MB 05 October 2021  
  • Public committee slides PDF 883 KB 05 October 2021  
  • Committee papers Managed Access Agreement PDF 400 KB 05 October 2021  

Draft guidance

  • Draft guidance  
  • Appraisal consultation document (online commenting)  
  • Appraisal consultation document (PDF version) PDF 143 KB 26 November 2020  
  • Committee papers PDF 3.82 MB 26 November 2020  
  • Public committee slides PDF 234 KB 26 November 2020  

Invitation to participate

  • Final scope PDF 197 KB 25 October 2019  
  • Equality impact assessment (Scoping) PDF 126 KB 25 October 2019  
  • Final stakeholder list PDF 186 KB 25 October 2019  
  • Draft scope and provisional stakeholder list comments table (post-referral) PDF 263 KB 25 October 2019  

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators  
  • Draft scope pre referral PDF 243 KB 29 March 2019  
  • Draft matrix pre referral PDF 184 KB 29 March 2019